Equities

Biosenic SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Biosenic SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.0023
  • Today's Change0.000 / -4.17%
  • Shares traded2.10m
  • 1 Year change-46.51%
  • Beta-0.8392
Data delayed at least 15 minutes, as of Feb 16 2026 13:29 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Biosenic SA formerly known as Bone Therapeutics SA is a Belgium-based company developing cell therapy products. The Company develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. It is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation. The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration. It also provides cell therapy platform for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO (Arsenic trioxide/ Oral arsenic trioxide).

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-4.77m
  • Incorporated2006
  • Employees3.00
  • Location
    Biosenic SARue Granbonpre 11, Batiment H (bte 24)MONT-SAINT-GUIBERT 1435BelgiumBEL
  • Phone+32 493097366
  • Fax+32 71121001
  • Websitehttps://www.biosenic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Procyon Corp4.20m-263.70k1.29m19.00--0.7027--0.307-0.0387-0.03870.61380.28171.472.329.90262,338.40-10.081.19-12.701.4478.0774.40-6.840.86912.41--0.00--6.353.53-367.38--17.32--
Saroja Pharma Industries India Ltd6.83m118.04k1.35m12.0011.380.892210.430.19763.173.17183.1240.41------61,135,500.00--5.16--11.566.8510.011.732.051.192.000.3926--32.1125.7617.7545.07157.98--
Universe Pharmaceuticals Inc15.05m-3.09m1.36m216.00--0.0287--0.0902-10.13-10.1339.1899.640.26025.881.3882,679.35-5.35-5.40-7.08-7.0935.2843.33-20.56-9.653.90-17.460.1416---22.44-10.2757.92--46.30--
Stemcell Holdings Inc8.41m2.61m1.38m------0.50080.16450.000080.000080.00030.00021.12--5.20--34.90--68.19--77.19--31.04------0.00--85.10--71.82------
Biosenic SA0.00-4.77m1.57m3.00---------0.0172-0.01720.00-0.07740.00----0.00-93.83-69.58---144.27-------3,376.80---3.46--------83.43------
Panacea Life Sciences Holdings Inc2.33m-6.46m1.60m40.00------0.6858-0.4554-0.45540.164-0.52550.15371.6210.1369,098.25-42.65-69.04---225.03-139.49-181.62-277.51-505.410.0285-2.122.58--46.59--12.33------
Kanabo Group PLC1.31m-9.41m1.64m17.00--0.2402--1.25-0.013-0.0130.00180.00940.105416.2843.8567,058.82-75.70-75.83-81.16-83.337.89---718.33-1,267.352.72-63.430.0337--48.42---16.26------
Bio Essence Corp476.62k-135.19k1.75m2.00------3.67-0.0042-0.00420.0149-0.08161.26--16.06282,835.00-35.64-40.94----69.2838.36-28.36-134.00---57.42-------17.08-286.98------
Data as of Feb 16 2026. Currency figures normalised to Biosenic SA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.